Targeting innate immune memory: a new paradigm for gout treatment

Abstract

Gout is a chronic inflammatory arthritis driven by monosodium urate crystal deposition and the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome activation, leading to interleukin-1β (IL-1β)-mediated inflammation. Recent studies reveal that hyperuricemia induces a state of immunological memory in innate immune cells through persistent epigenetic and metabolic reprogramming of monocytes and macrophages. These alterations enhance the responsiveness of innate immune cells, leading to exaggerated inflammatory reactions upon subsequent stimulation. This review synthesizes recent studies that elucidate how metabolic shifts (e.g., increased glycolysis and fumarate accumulation) and epigenetic changes (e.g., altered histone methylation and DNA methylation) reinforce this pathogenic memory. Importantly, these mechanistic insights provide the rationale for emerging therapeutic strategies: IL-1β inhibitors aim to interrupt the central inflammatory axis; metabolic modulators (e.g., metformin, statins) seek to reverse the trained metabolic state; and epigenetic therapies [e.g., histone deacetylase (HDAC) or DNA methyltransferase (DNMT) inhibitors] hold potential to reset dysregulated immune programming. Collectively, this review argues that multi-layered intervention, such as cytokine blockade for acute control, coupled with metabolic or epigenetic remodeling for long-term reprogramming, could yield sustained disease suppression and reduced flare frequency in gout.

Keywords

Gout / immunomodulation / therapy / innate immune memory / CHIP

References

[1] Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020; 50: S11-6.

[2] Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord. 2024; 25: 1047.

[3] Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021; 397: 1843-55.

[4] Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017; 15: 158.

[5] Keenan RT. The biology of urate. Semin Arthritis Rheum. 2020; 50: S2-10.

[6] Yin H, Liu N, Chen J. The Role of the Intestine in the Development of Hyperuricemia. Front Immunol. 2022; 13: 845684.

[7] Singh AK, Durairajan SSK, Iyaswamy A, Williams LL. Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: Insights and therapeutic strategies. World J Gastroenterol. 2024; 30: 4404-10.

[8] Wei J, Zhang Y, Dalbeth N, Terkeltaub R, Yang T, Wang Y, et al. Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts. Arthritis Rheumatol. 2022; 74: 682-91.

[9] Leask MP, Crișan TO, Ji A, Matsuo H, Köttgen A, Merriman TR. The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies. Nat Rev Rheumatol. 2024; 20: 510-23.

[10] Badii M, Gaal O, Popp RA, Crișan TO, Joosten LAB. Trained immunity and inflammation in rheumatic diseases. Joint Bone Spine. 2022; 89: 105364.

[11] Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352: aaf1098.

[12] Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host’s Response to Pathogens. Cell Host Microbe. 2019; 25: 13-26.

[13] Netea MG, Joosten LAB. Trained innate immunity: Concept, nomenclature, and future perspectives. J Allergy Clin Immunol. 2024; 154: 1079-84.

[14] Bekkering S, Domínguez-Andrés J, Joosten LAB, Riksen NP, Netea MG. Trained Immunity: Reprogramming Innate Immunity in Health and Disease. Annu Rev Immunol. 2021; 39: 667-93.

[15] Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, et al. Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. Cell. 2018; 172: 147-61.e12.

[16] Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014; 345: 1250684.

[17] Ferreira AV, Domínguez-Andrés J, Merlo Pich LM, Joosten LAB, Netea MG. Metabolic Regulation in the Induction of Trained Immunity. Semin Immunopathol. 2024; 46: 7.

[18] Fanucchi S, Domínguez-Andrés J, Joosten LAB, Netea MG, Mhlanga MM. The Intersection of Epigenetics and Metabolism in Trained Immunity. Immunity. 2021; 54: 32-43.

[19] Cabău G, Crișan TO, Klück V, Popp RA, Joosten LAB. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunol Rev. 2020; 294: 92-105.

[20] Tercan H, Riksen NP, Joosten LAB, Netea MG, Bekkering S. Trained Immunity: Long-Term Adaptation in Innate Immune Responses. Arterioscler Thromb Vasc Biol. 2021; 41: 55-61.

[21] Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020; 16: 75-86.

[22] Badii M, Gaal OI, Cleophas MC, Klück V, Davar R, Habibi E, et al. Urate-induced epigenetic modifications in myeloid cells. Arthritis Res Ther. 2021; 23: 202.

[23] Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41.

[24] Fok ET, Davignon L, Fanucchi S, Mhlanga MM. The lncRNA Connection Between Cellular Metabolism and Epigenetics in Trained Immunity. Front Immunol. 2019; 9: 3184.

[25] Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019; 366: eaan4673.

[26] Sikking MA, Stroeks SLVM, Waring OJ, Henkens MTHM, Riksen NP, Hoischen A, et al. Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist’s Point of View. J Am Heart Assoc. 2023; 12: e030603.

[27] Bekele DI, Patnaik MM. Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms. Rheum Dis Clin North Am. 2020; 46: 429-44.

[28] Arends CM, Weiss M, Christen F, Eulenberg-Gustavus C, Rousselle A, Kettritz R, et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica. 2020; 105: e264-7.

[29] Merriman TR, Joosten LAB. CHIP and gout: trained immunity? Blood. 2022; 140: 1054-6.

[30] Agrawal M, Niroula A, Cunin P, McConkey M, Shkolnik V, Kim PG, et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022; 140: 1094-103.

[31] Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021; 88: 105092.

[32] Kim SK. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout. J Rheum Dis. 2022; 29: 140-53.

[33] Liu YR, Wang JQ, Li J. Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Front Immunol. 2023; 14: 1137822.

[34] Moorlag SJCFM, Röring RJ, Joosten LAB, Netea MG. The role of the interleukin-1 family in trained immunity. Immunol Rev. 2018; 281: 28-39.

[35] Giesbrecht K, Eberle ME, Wölfle SJ, Sahin D, Sahr A, Oberhardt V, et al. IL-1β As Mediator of Resolution That Reprograms Human Peripheral Monocytes toward a Suppressive Phenotype. Front Immunol. 2017; 8: 899.

[36] Paik S, Kim JK, Silwal P, Sasakawa C, Jo EK. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021; 18: 1141-60.

[37] Bekkering S, Arts RJW, Novakovic B, Kourtzelis I, van der Heijden CDCC, Li Y, et al. Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell. 2018; 172: 135-46.e9.

[38] Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, et al. Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metab. 2016; 24: 807-19.

[39] Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018; 23: 89-100.e5.

[40] Flores-Gomez D, Hobo W, van Ens D, Kessler EL, Novakovic B, Schaap NPM, et al. Interleukin-1β induces trained innate immunity in human hematopoietic progenitor cells in vitro. Stem Cell Reports. 2024; 19: 1651-64.

[41] Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013; 25: 469-84.

[42] Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015; 54: 2134-44.

[43] Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21: 248-55.

[44] Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, de Torre-Minguela C, Cerón-Carrasco JP, Pérez-Sánchez H, et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol. 2019; 15: 560-4.

[45] Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019; 10: 128.

[46] Sánchez-Fernández A, Skouras DB, Dinarello CA, López-Vales R. OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Front Immunol. 2019; 10: 2578.

[47] Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018; 115: E1530-9.

[48] Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15: 473-84.

[49] Cobo I, Murillo-Saich J, Alishala M, Guma M. Epigenetic and Metabolic Regulation of Macrophages during Gout. Gout Urate Cryst Depos Dis. 2023; 1: 137-51.

[50] Tseng CC, Liao WT, Wong MC, Chen CJ, Lee SC, Yen JH, et al. Cell lineage-specific methylome and genome alterations in gout. Aging (Albany NY). 2021; 13: 3843-65.

[51] Gu H, Yu H, Qin L, Yu H, Song Y, Chen G, et al. MSU crystal deposition contributes to inflammation and immune responses in gout remission. Cell Rep. 2023; 42: 113139.

[52] Renaudin F, Orliaguet L, Castelli F, Fenaille F, Prignon A, Alzaid F, et al. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages. Ann Rheum Dis. 2020; 79: 1506-14.

[53] Riksen NP, Netea MG. Immunometabolic control of trained immunity. Mol Aspects Med. 2021; 77: 100897.

[54] Ferreira AV, Domiguéz-Andrés J, Netea MG. The Role of Cell Metabolism in Innate Immune Memory. J Innate Immun. 2022; 14: 42-50.

[55] McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, et al. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. JAMA Intern Med. 2024; 184: 650-60.

[56] Marrugo J, Santacroce LM, Paudel ML, Fukui S, Turchin A, Tedeschi SK, et al. Gout risk in adults with pre-diabetes initiating metformin. Ann Rheum Dis. 2024; 83: 1368-74.

[57] Stathopoulou C, Nikoleri D, Bertsias G. Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. Immunotherapy. 2019; 11: 813-29.

[58] Makki K, Taront S, Molendi-Coste O, Bouchaert E, Neve B, Eury E, et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One. 2014; 9: e92684.

[59] Shao P, Ma L, Ren Y, Liu H. Modulation of the immune response in rheumatoid arthritis with strategically released rapamycin. Mol Med Rep. 2017; 16: 5257-62.

[60] Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, et al. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout. Rheumatology (Oxford). 2024; 63: 1058-67.

[61] Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006; 6: 358-70.

[62] Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. Front Pharmacol. 2023; 14: 1096999.

[63] Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Meta-analysis. Curr Med Chem. 2024; 31: 1726-39.

[64] Sheridan A, Wheeler-Jones CPD, Gage MC. The Immunomodulatory Effects of Statins on Macrophages. Immuno. 2022; 2: 317-43.

[65] Keller SF, Rai SK, Lu N, Oza A, Jorge AM, Zhang Y, et al. Statin use and mortality in gout: A general population-based cohort study. Semin Arthritis Rheum. 2018; 48: 449-55.

[66] Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019; 20: 207-20.

[67] Arts RJ, Joosten LA, Netea MG. Immunometabolic circuits in trained immunity. Semin Immunol. 2016; 28: 425-30.

[68] van der Heijden CDCC, Noz MP, Joosten LAB, Netea MG, Riksen NP, Keating ST. Epigenetics and Trained Immunity. Antioxid Redox Signal. 2018; 29: 1023-40.

[69] Wang Z, Zhao Y, Phipps-Green A, Liu-Bryan R, Ceponis A, Boyle DL, et al. Differential DNA Methylation of Networked Signaling, Transcriptional, Innate and Adaptive Immunity, and Osteoclastogenesis Genes and Pathways in Gout. Arthritis Rheumatol. 2020; 72: 802-14.

[70] Novakovic B, Habibi E, Wang SY, Arts RJW, Davar R, Megchelenbrink W, et al. β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance. Cell. 2016; 167: 1354-68.e14.

[71] Tseng CC, Wong MC, Liao WT, Chen CJ, Lee SC, Yen JH, et al. Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout. Int J Mol Sci. 2020; 21: 4702.

[72] Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011; 6: e17388.

[73] Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017; 18: 985-94.

[74] Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The Metabolic Signature of Macrophage Responses. Front Immunol. 2019; 10: 1462.

[75] Qiu J, Wu B, Goodman SB, Berry GJ, Goronzy JJ, Weyand CM. Metabolic Control of Autoimmunity and Tissue Inflammation in Rheumatoid Arthritis. Front Immunol. 2021; 12: 652771.

[76] Liu S, Yang J, Wu Z. The Regulatory Role of α-Ketoglutarate Metabolism in Macrophages. Mediators Inflamm. 2021; 2021: 5577577.

[77] Shuttleworth SJ, Bailey SG, Townsend PA. Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010; 11: 1430-8.

[78] Nazri JM, Oikonomopoulou K, de Araujo ED, Kraskouskaya D, Gunning PT, Chandran V. Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions. Crit Rev Clin Lab Sci. 2023; 60: 300-20.

[79] Tordera RM, Cortés-Erice M. Role of Histone Deacetylases in Monocyte Function in Health and Chronic Inflammatory Diseases. In: Pedersen SHF, editor. Reviews of Physiology, Biochemistry and Pharmacology. Cham: Springer International Publishing; 2021. pp. 1-47.

[80] Cleophas MCP, Crişan TO, Klück V, Hoogerbrugge N, Netea-Maier RT, Dinarello CA, et al. Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. Arthritis Res Ther. 2019; 21: 50.

[81] Wang J, Wang X, Ding X, Huang T, Song D, Tao H. EZH2 is associated with cartilage degeneration in osteoarthritis by promoting SDC1 expression via histone methylation of the microRNA-138 promoter. Lab Invest. 2021; 101: 600-11.

[82] De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 2007; 130: 1083-94.

[83] Chen L, Wu Y, Wu Y, Wang Y, Sun L, Li F. The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway. Sci Rep. 2016; 6: 29176.

[84] Fok ET, Moorlag SJCFM, Negishi Y, Groh LA, Dos Santos JC, Gräwe C, et al. A chromatin-regulated biphasic circuit coordinates IL-1β-mediated inflammation. Nat Genet. 2024; 56: 85-99.

[85] Fanucchi S, Fok ET, Dalla E, Shibayama Y, Börner K, Chang EY, et al. Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments. Nat Genet. 2019; 51: 138-50.

[86] Qing YF, Zheng JX, Tang YP, Dai F, Dong ZR, Zhang QB. LncRNAs Landscape in the patients of primary gout by microarray analysis. PLoS One. 2021; 16: e0232918.

[87] Liu YF, Xing GL, Chen Z, Tu SH. Long non-coding RNA HOTAIR knockdown alleviates gouty arthritis through miR-20b upregulation and NLRP3 downregulation. Cell Cycle. 2021; 20: 332-44.

[88] Fang L, Xu X, Lu Y, Wu Y, Li J. Long noncoding RNA SNHG8 accelerates acute gouty arthritis development by upregulating AP3D1 in mice. Bioengineered. 2021; 12: 9803-15.

[89] Terada C, Oh K, Tsubaki R, Chan B, Aibara N, Ohyama K, et al. Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry. Nat Commun. 2023; 14: 7972.

[90] Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis. 2022; 13: 644.

[91] Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023; 142: 2235-46.

[92] Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021; 161: 98-105.

[93] Chavakis T, Wielockx B, Hajishengallis G. Inflammatory Modulation of Hematopoiesis: Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders. Annu Rev Physiol. 2022; 84: 183-207.

[94] Busque L, Sun M, Buscarlet M, Ayachi S, Feroz Zada Y, Provost S, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020; 4: 2430-8.

[95] Verma D, Särndahl E, Andersson H, Eriksson P, Fredrikson M, Jönsson JI, et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production. PLoS One. 2012; 7: e34977.

[96] Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005; 65: 6305-11.

[97] Oh YS, Jeong SG, Cho GW. Anti-senescence effects of DNA methyltransferase inhibitor RG108 in human bone marrow mesenchymal stromal cells. Biotechnol Appl Biochem. 2015; 62: 583-90.

[98] Abplanalp WT, Schuhmacher B, Cremer S, Merten M, Shumliakivska M, Macinkovic I, et al. Cell-intrinsic effects of clonal hematopoiesis in heart failure. Nat Cardiovasc Res. 2023; 2: 819-34.

[99] Hull EE, Montgomery MR, Leyva KJ. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int. 2016; 2016: 8797206.